PP-01 High Dose for Cannabis Withdrawal
Phase-Based Progress Estimates
Effectiveness
Safety
Cannabis Withdrawal+1 More
PP-01 High Dose - CombinationProductEligibility
18 - 65
All Sexes
What conditions do you have?
Select
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select
Study Summary
This study will be a randomized, double-blind, placebo-controlled, multicenter trial conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with discontinuing cannabis in participants with moderate to severe Cannabis Use Disorder (CUD). The study will enroll approximately 225 participants with moderate to severe CUD and will include 5 arms, including a placebo arm, to help assess the incidence and severity of withdrawal symptoms in heavy long-term users of cannabis. Participants receive study medication for 34 days and participate in 11 visits (7 at a clinic and 4 telemedicine).
Eligible Conditions
- Cannabis Withdrawal
Treatment Effectiveness
Effectiveness Progress
Other trials for Cannabis Withdrawal
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: Over 5 days
Over 5 days
Substance Withdrawal Syndrome
Evaluation of a patient reported outcome measure of cannabis withdrawal over 5 days
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Other trials for Cannabis Withdrawal
Trial Design
5 Treatment Groups
Nabilone
1 of 5
Gabapentin
1 of 5
PP-01 High Dose
1 of 5
PP-01 Low Dose
1 of 5
Placebo
1 of 5
Active Control
Experimental Treatment
Non-Treatment Group
225 Total Participants · 5 Treatment Groups
Primary Treatment: PP-01 High Dose · Has Placebo Group · Phase 2
PP-01 High Dose
CombinationProduct
Experimental Group · 1 Intervention: PP-01 High Dose · Intervention Types: CombinationProductPP-01 Low Dose
CombinationProduct
Experimental Group · 1 Intervention: PP-01 Low Dose · Intervention Types: CombinationProductNabilone
Drug
ActiveComparator Group · 1 Intervention: Nabilone · Intervention Types: DrugPlacebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: DrugGabapentin
Drug
ActiveComparator Group · 1 Intervention: Gabapentin · Intervention Types: DrugTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: over 5 days
Who is running the clinical trial?
PleoPharma, Inc.Lead Sponsor
Jay Constantine, MDStudy DirectorPleoPharma, Inc.
Eligibility Criteria
Age 18 - 65 · All Participants · 9 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You are generally healthy.\n
You have a current diagnosis of moderate to severe CUD as confirmed by a licensed physician or psychologist or addiction medicine specialist.
You have a body mass index (BMI) of 18.0 to 38.0 kg/m2, inclusive.
You are seeking to discontinue cannabis use because of withdrawal symptoms.
You are willing to comply with all study procedures including twice weekly visits, daily evening video calls, restrictions, and availability for the duration of the study.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| New Jersey | 100.0% |
How old are they?
| 18 - 65 | 100.0% |
What site did they apply to?
| Hassman Research Institute | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Why did patients apply to this trial?
- "I have recently and in the past tried to quit smoking marijuana but the effects on my nerves gets to me ...its like i need a drag just to function sometimes"
What questions have other patients asked about this trial?
- "How much is compensation and also will i be paid for travel time?"
How many prior treatments have patients received?
| 0 | 100.0% |
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments